Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ (2016) 1.06

Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. N Engl J Med (2016) 1.06

Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others? J Atr Fibrillation (2016) 0.75

Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice? Arrhythm Electrophysiol Rev (2016) 0.75

Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. N Engl J Med (2016) 0.75

Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents. Curr Drug ther (2016) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome: The British Heart Foundation RITA-3 Randomized Trial. J Am Coll Cardiol (2015) 3.91

The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol (2007) 0.94